Federally Funded Clinical Trials

Federally Funded Clinical Trials

Our research sites continue to participate in Federally-funded research through NRG Oncology.  The following protocols are currently open to accrual.  Please visit the CTSU members' website for full information about these protocols.


Protocol Activation (Date Opened to Accrual): 08/22/2013

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

ClinicalTrials.gov Identifier: NCT01872975



Protocol Activation (Closed to Accrual)

A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation

ClinicalTrials.gov Identifier: NCT02003209


Protocol Activation (Date Opened to Accrual): 09/03/2013

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer

e3 Breast Cancer Study - evaluating everolimus with endocrine therapy

ClinicalTrials.gov Identifier: NCT01674140


NSABP B-55/BIG 6-13

Protocol Activation (Date Opened to Accrual): 07/03/2014

A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

ClinicalTrials.gov Identifier: NCT02032823


NRG - BR003

Protocol Activation (Date Opened to Accrual): 06/26/2015

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

ClinicalTrials.gov Identifier: NCT02488967

NRG - GI002

Protocol Activation (Date Opened to Accrual): 10/12/2016

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

ClinicalTrials.gov Identifier: NCT02921256

NRG - BR005

Protocol Activation (Date Opened to Accrual): 04/13/2017 

A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients With Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery

ClinicalTrials.gov Identifier: NCT03188393